

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO			Complete if Known Application Number 10/785,497 Filing Date February 24, 2004 First Named Inventor Mark W. Becker et al. Art Unit 1657 Examiner Name P.C. Martin Attorney Docket Number 249.P2	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				
Sheet	1	of	2	

[illegible][illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

* EXAMINER: Include if reference concerns whether or not citation is in conformance with MPEP 6009. Draw line through citation if not in conformance and state reason. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with a single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(ii)) because that Citation was filed after June 30, 2003 or is available in the IFW. ** CITE NO.: Those document(s) which are marked with two asterisks (**) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office, in a prior application referred to in this application for an earlier filing date under 35 U.S.C. 120. * Applicant's unique citation designation number (optional). * For Search Code (USPTO) related documents at www.uspto.gov under MPEP 6014. * U.S. Patent: That citation that issued the document, by the two-letter code (e.g., US, EP, ST, etc.) and the year of the patent document, are indication of the year of the origin of the cited document. * Serial number of the patent document. * Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. * Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/785,497	
		Filing Date	February 24, 2004	
		First Named Inventor	Mark W. Becker et al.	
		Art Unit	1657	
		Examiner Name	P.C. Martin	
Sheet	2	2	Attorney Docket Number	249.P2

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	Beach et al. (1998) "Chemotherapeutic agents for human immunodeficiency virus infection: Mechanism of action, pharmacokinetics, metabolism, and adverse reactions," <i>Clinical Therapeutics</i> 20(1):2-25	
	CB	CAMP, N.P. et al. (1995) "Synthesis of Peptide Analogues Containing Phosphonamide Methyl Ester Functionality: HIV-1 Proteinase Inhibitors Possessing Unique Cell Uptake Properties,"	
	CC	Cihlar et al. (2006) "Suppression of HIV-1 Protease Inhibitor Resistance by Phosphonate-mediated solvent anchoring," <i>Journal of Molecular Biology</i> 363(3):635-647	
	CD	Eddershaw et al. (2000) "ADME/PK as part of a rational approach to drug discovery" <i>Drug Discovery Today</i> 5(9):409-414	
	CE	FRANCHETTI, P., et al. (1998) "Potent and Selective Inhibitors of Human Immunodeficiency Virus Protease Structurally Related to L-94,746," <i>Antiviral Chemistry & Chemotherapy</i> 9(4):303-309	
	CF	GULICK (2003) "New Antiviral Drugs," <i>Clinical Microbiology and Infectious Diseases</i> 9:186-193	
	CG	Hoggard et al. (2002) "Intracellular pharmacology of nucleoside analogues and protease inhibitors: role of transporter molecules," <i>Current Opinion in Infectious Diseases</i> 15(1):3-8	
	CH	Kiso et al. (1999) "Design of small peptidomimetic HIV-1 Protease Inhibitors and Prodrug Forms," 6(5/6):275-281	
	CI	Krise et al. (1996) "Prodrugs of Phosphates, Phosphonates, and Phosphinates," <i>Advanced Drug Delivery Reviews</i> 19(2):287-310	
	CJ	Kubota et al. (1998) "Novel inhibitory effects of gamma-glutamylcysteine ethyl ester against human immunodeficiency virus type 1 production and propagation," <i>Antimicrobial Agents and Chemotherapy</i> 42(5):1200-1205	
	CK	Lee et al. (2002) "In Vivo and In Vitro Characterization of GS 7340, an isopropylalanine phenyl ester prodrug of Tenofovir: selective intracellular activation of GS 7340 leads to preferential distribution in lymphatic tissues. 9th Conference of Retroviruses and Opportunistic Infections, Abstract No. 384T	
	CL	Robbins et al. (1998) "Anti-Human Immunodeficiency Virus Activity and Cellular Metabolism of A Potential Prodrug of the Acyclic Nucleoside Phosphonate 9-R-(2-Phosphonomethoxypropyl) Adenine (PMPA), Bis(Isopropoxyoxymethylcarbonyl) PMPA" <i>Antimicrobial Agents and Chemotherapy</i> 42(3):612-617	
	CL	Zimra et al. (2000) "Uptake of pivaloyloxymethyl butyrate into leukemic esterase-catalyzed hydrolysis," <i>Journal of Cancer Research and Clinical Oncology</i> 126(12):693-698	

Examiner Signature	Date Considered
--------------------	-----------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of the form with next communication to applicant. ² CITE NO.: Those document(s) which are marked with an asterisk (*) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120.

³Applicant's unique citation designation number (optional). ⁴Applicant is to place a check mark here if English language Translation is attached.